These results imply that GPR30 is a stimulation factor in tamoxifen-resistant xenograft growth, and inhibiting GPR30 activation by targeted therapy could restore the curative effect of endocrine treatment to tamoxifen-resistant breast cancer. Here, GPER1 is linked to breast carcinoma.